This project aims to improve the understanding of what causes and stimulates inflammation in SpA patients. Specifically, the project tests the hypothesis that the barrier function of the gut is impaired in SpA patients, which could promote the entry of bacterial components from the gut into the body. Such bacterial components can activate directly or indirectly pathogenic immune responses.
In transcriptome analysis of CD14+ monocy- tes 957 Affymetrix probe sets were differen- tially expressed between axSpA patients and HC (Berlin). Coexpression analysis with refe- rence transcriptomes found an overlap of these IDs with late myeolopoesis and responses trigged by G-CFS mobilization and by LPS and TNF suggesting changes in myelopoiesis.
In the project patient-reported disease activity scores, patient reported functional scores as well as the patient acceptable symptom state (PASS) score are included to determine relations of translocation biomarkers to these patient reported outcome parameters.